Formestane

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Aschwole (talk | contribs) at 17:45, 10 January 2014 (→‎Synthesis). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Formestane
Clinical data
Other names4-hydroxyandrost-4-ene-3,17-dione
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.153.838 Edit this at Wikidata
Chemical and physical data
FormulaC19H26O3
Molar mass302.408 g/mol g·mol−1
3D model (JSmol)
  • O=C4C(/O)=C3/CC[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4
  • InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1 checkY
  • Key:OSVMTWJCGUFAOD-KZQROQTASA-N checkY
 ☒NcheckY (what is this?)  (verify)

Formestane (Lentaron) is a type I, steroidal aromatase inhibitor. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection.

Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor.

Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified.

It is selective.[1]

Synthesis

Oxidation of testosterone with osmium tetraoxide gives the corresponding 4,5-glycol () of undefined stereochemistry. By the method of formation, both hydroxyls probably have the same b-configuration. This product the undergoes spontaneous b-dehydration to the enol hydroxide derivative formestane. Actually, product still needs oxidating in final step, but get general idea.

References

  1. ^ Pérez Carrión R, Alberola Candel V, Calabresi F; et al. (1994). "Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer". Ann. Oncol. 5 Suppl 7: S19–24. PMID 7873457. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)